Adverum Biotech
Sahil Nallan is a seasoned professional with extensive experience in the biotechnology sector, currently serving as a Senior Scientist at Adverum Biotechnologies, Inc. since May 2019, following roles as Scientist II and Process Development Engineer II. Prior experience includes a position as Research Associate II at Vaxart Inc. from July 2016 to May 2019, and a brief tenure as a Research Assistant at Danielle Tullman-Ercek Labs focused on biofuel research. Sahil also possesses a background in education as an instructor and community sales representative at Revolution Prep, where significant SAT score improvements were achieved. Early volunteer work at the Regional Medical Center of San Jose involved patient care and training new volunteers. Sahil earned a Bachelor of Science in Molecular Environmental Biology from the University of California, Berkeley, graduated in 2016.
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.